African Horse Sickness Treatment Market Report

Global African Horse Sickness Treatment Market Size

The global African Horse Sickness Treatment Market was valued at USD 11.33 billion in 2025 and it is expected to reach USD 45.49 billion by 2034 from USD 13.22 billion in 2026, growing at a CAGR of 16.7 %. From 2026 to 2034.

African Horse Sickness (AHS) is a highly infectious, vector-borne viral disease that affects equines, including horses, mules, donkeys, and zebras. Caused by the African horse sickness virus (AHSV), which belongs to the Orbivirus genus of the Reoviridae family, the disease is transmitted primarily through the bite of infected midges of the Culicoides species. AHS presents in multiple clinical forms, with mortality rates reaching up to 95% in naïve horse populations, making it one of the most lethal equine diseases globally.

Moreover, the African horse sickness treatment market includes vaccines, antiviral therapies, supportive care treatments, and diagnostic tools aimed at managing outbreaks and preventing transmission. While there is no specific cure for AHS, treatment primarily focuses on symptom management, hydration, and rest, with vaccination being the primary preventive strategy. The market has seen growing interest due to increased cross-border animal movement, climate change-induced expansion of vector habitats, and rising investments in equine health research.

According to the World Organisation for Animal Health (WOAH), also known as the OIE, AHS remains endemic in sub-Saharan Africa but poses a significant threat to Europe, the Middle East, and parts of Asia, where sporadic outbreaks have occurred. Also, as per the Food and Agriculture Organization (FAO) of the United Nations, over 30 countries are considered at risk of AHS incursion, highlighting the need for robust surveillance and treatment infrastructure. With global trade and equine sports becoming increasingly interconnected, the demand for effective AHS treatment solutions is gaining strategic importance in both veterinary and economic contexts.

MARKET DRIVERS

Rising Outbreaks and Expansion of AHS Beyond Endemic Regions

A key factor propelling the African horse sickness treatment market is the increasing frequency and geographic spread of AHS outbreaks beyond traditionally endemic regions. Historically confined to sub-Saharan Africa, AHS has recently been reported in areas such as the Iberian Peninsula, the Middle East, and South Asia, raising alarms among veterinary and agricultural authorities.

According to the European Food Safety Authority (EFSA), the first confirmed case of AHS in Spain since 2020 was recorded in early 2025, signaling a resurgence in Europe after years of containment.

Also, as per the Food and Agriculture Organization (FAO), between 2020 and 2025, AHS cases outside Africa increased by nearly 60%, attributed largely to climate change, increased international equine movement, and the spread of competent insect vectors into new territories.

These developments have heightened the urgency for improved treatment and preventive strategies, particularly among equine-rearing communities, racing industries, and governmental livestock departments. In response, veterinary pharmaceutical companies are ramping up R&D investments into next-generation vaccines and diagnostics.

Increased Investment in Equine Healthcare and Vaccine Development

One more major factor fueling the growth of the African horse sickness treatment market is the surge in investment in equine healthcare, particularly vaccine development and distribution. Governments and private stakeholders are recognizing the economic and ecological implications of uncontrolled AHS outbreaks, prompting substantial financial commitments toward vaccine innovation and mass immunization programs. These funds have enabled biotech firms and veterinary pharma companies to accelerate trials for novel live-attenuated and recombinant vaccines offering broader serotype coverage and improved safety profiles.

Also, private sector players such as Boehringer Ingelheim and MSD Animal Health have expanded their production capacities to meet this rising demand, further reinforcing the market’s upward trajectory. This convergence of public and private investment is playing a pivotal role in strengthening the African horse sickness treatment market and enhancing global preparedness against future outbreaks.

MARKET RESTRAINTS

Limited Availability and Accessibility of Effective Vaccines

A significant restraint for the African horse sickness treatment market is the limited availability and accessibility of safe, effective, and broadly protective vaccines, especially in low-income and endemic regions. While several vaccines exist, they often come with limitations such as serotype specificity, adverse side effects, and challenges in storage and distribution.

According to the World Organisation for Animal Health (WOAH), current live-attenuated vaccines used in many African countries provide immunity against only a few of the nine known AHSV serotypes, requiring multiple inoculations for comprehensive protection. This not only complicates immunization campaigns but also increases costs and logistical burdens, particularly in rural areas with poor cold-chain infrastructure.

Moreover, regulatory bottlenecks delay the approval and deployment of newer generation vaccines. Consequently, many regions remain reliant on outdated or partially effective formulations.

Private manufacturers also face constraints in scaling production due to high R&D costs and uncertain return on investment, especially in markets with limited purchasing power. Also, only two companies Boehringer Ingelheim and Ceva Santé Animale currently supply AHS vaccines at a commercial scale, creating supply-side vulnerabilities that hinder market growth.

Inadequate Surveillance and Reporting Systems in Endemic Areas

Inadequate surveillance and reporting systems in AHS-endemic regions pose a major challenge to the effectiveness of treatment and prevention efforts, thereby constraining the African horse sickness treatment market. Many affected countries lack standardized data collection mechanisms, leading to underreporting of outbreaks and delayed response measures. This hampers early detection and containment, allowing the disease to spread unchecked within and beyond national borders.

Furthermore, there is weak coordination between veterinary services, local authorities, and international organizations that limits the efficacy of outbreak control strategies. As per the World Organisation for Animal Health (WOAH), in 2023, nearly half of the African countries surveyed lacked real-time digital reporting platforms for animal disease monitoring, impeding rapid information sharing essential for coordinated action.

This gap in surveillance infrastructure discourages investment in treatment development, as pharmaceutical companies struggle to assess true disease burden and market potential. According to the International Federation for Animal Health (IFAH), the absence of reliable epidemiological data contributes to a reduction in investor confidence for AHS-related products compared to other animal diseases with better reporting systems.Without stronger surveillance frameworks, the African Horse Sickness Treatment Market will continue to face structural barriers that limit its reach and impact.

MARKET OPPORTUNITIES

Advancements in Next-Generation Vaccine Technologies

Among the most promising opportunities in the African horse sickness treatment market lies in the development and adoption of next-generation vaccine technologies. Traditional live-attenuated vaccines, while widely used, suffer from limitations such as incomplete serotype coverage, potential reversion to virulence, and adverse reactions in some equines. These drawbacks have spurred interest in recombinant DNA-based and mRNA vaccine platforms that offer safer, more targeted, and potentially multivalent protection against multiple AHSV strains.

According to the International Livestock Research Institute (ILRI), recent advancements in molecular biology have enabled scientists to develop prototype vaccines using reverse genetics techniques that can be tailored to neutralize all nine AHSV serotypes simultaneously.

Moreover, the success of mRNA technology in human vaccines during the pandemic has prompted exploration of its application in veterinary medicine. Companies are investing in RNA-based approaches for AHS, aiming to deliver faster immune responses and easier manufacturing scalability. With ongoing research and regulatory support, next-generation vaccines represent a transformative opportunity to enhance the market and improve disease control globally.

Growing Demand for Cross-Border Equine Trade and Sports Activities

The increasing globalization of equine trade and the rise in international equestrian events present a significant opportunity for the African horse sickness treatment market. As countries engage in more frequent import and export of horses for breeding, racing, and competition purposes, the risk of AHS introduction into non-endemic regions has surged, necessitating stringent health protocols and prophylactic treatments.

Also, national veterinary authorities in importing countries have tightened quarantine and immunization requirements. As per the U.S. Department of Agriculture’s Animal and Plant Health Inspection Service (USDA-APHIS), all horses entering the U.S. from AHS-affected regions must provide proof of vaccination and negative test results, further boosting the need for compliant treatment solutions.

This trend underscores the expanding commercial potential for AHS treatment products, particularly in regions previously unaffected by the disease.

MARKET CHALLENGES

Climate Change and Vector Proliferation

Climate change is emerging as a major challenge in controlling African Horse Sickness (AHS), significantly influencing the proliferation of Culicoides midges the primary vectors responsible for transmitting the virus. Rising temperatures, shifting rainfall patterns, and prolonged warm seasons have extended the breeding periods and geographic range of these insects, increasing the likelihood of AHS outbreaks in new and previously unaffected regions.

According to the Intergovernmental Panel on Climate Change (IPCC), global average temperatures have risen by approximately 1.2°C since pre-industrial times, directly impacting vector ecology. Also, as per studies published by the European Centre for Disease Prevention and Control (ECDC), Culicoides populations have expanded northward into Central and Eastern Europe, bringing AHS closer to major equine hubs.

In response, veterinary authorities in countries like Germany, France, and Turkey have heightened surveillance and biosecurity measures. However, predicting and mitigating vector activity remains complex due to the dynamic nature of climate-induced changes. This environmental uncertainty complicates vaccination planning and outbreak response, posing a formidable challenge to the stability and effectiveness of the African horse sickness treatment market.

Regulatory Hurdles and Delayed Approvals for New Treatments

Regulatory complexities and delayed approvals for new African Horse Sickness (AHS) treatments pose a persistent challenge to market growth and innovation. The development and commercialization of vaccines, diagnostics, and therapeutic agents require rigorous evaluation by national and international regulatory bodies, often resulting in lengthy approval timelines that hinder timely access to advanced solutions.

This delay discourages investment from pharmaceutical companies, particularly small and medium-sized enterprises that lack the resources to navigate protracted approval processes.

In addition, harmonization of standards across regions remains an issue. As per the Food and Agriculture Organization (FAO), discrepancies in import regulations and vaccine certification criteria between the European Union and African countries create logistical barriers for cross-border use of approved products.

Addressing these hurdles is crucial for accelerating the availability of life-saving interventions and strengthening the overall resilience of the African horse sickness treatment market.

REPORT COVERAGE

SEGMENTAL ANALYSIS

By Clinical Form Insights

The mixed form of African Horse Sickness (AHS) accounted for the largest segment in the treatment market, capturing 38.5% of total market demand in 2025. This clinical manifestation combines symptoms of both the cardiac and pulmonary forms, leading to high mortality rates and necessitating intensive veterinary intervention. Also, the complexity of this form increases the need for broad-spectrum treatments, including supportive care, hydration therapies, and emergency vaccination protocols.

Moreover, the mixed form’s unpredictable progression makes it a priority for diagnostic and therapeutic development. Veterinary hospitals and equine clinics in high-risk zones frequently encounter this form, prompting greater investment in multi-modal treatment approaches.

The pulmonary or Dunkop form of African Horse Sickness is the fastest-growing segment in the treatment market, projected to expand at a CAGR of 9.2% from 2025 to 2033, outpacing other clinical manifestations due to its increasing prevalence in warmer climates and expanding vector territories. This form, characterized by acute respiratory distress and high fever, has seen a surge in incidence rates, especially in newly affected regions such as Southern Europe and the Middle East.

Furthermore, the pulmonary form often presents in outbreaks involving imported horses, triggering heightened biosecurity measures and diagnostic investments. These factors collectively position the pulmonary form as the most rapidly evolving segment within the market.

By Diagnosis Insights

Preventive diagnosis commanded the African Horse Sickness (AHS) treatment market, accounting for 43.1% of total market share in 2025. This segment includes pre-movement testing, routine surveillance, and vaccination-based immunity assessments aimed at mitigating outbreak risks before they escalate into full-scale epidemics.

Like, according to the World Organisation for Animal Health (WOAH), preventive diagnostic protocols are mandatory for international equine movement, with over 15,000 horses transported globally for competitions and breeding purposes in 2023 alone. Each of these animals must undergo AHS-specific testing and vaccination certification, significantly boosting demand for preventive tools.

Apart from these, national veterinary authorities in high-risk countries have implemented large-scale screening programs. Also, private diagnostic firms such as IDEXX Laboratories and Thermo Fisher Scientific have expanded their equine disease testing portfolios, recognizing the growing commercial potential of preventive diagnosis. Like, preventive diagnostic revenues in the AHS space grew in 2023 compared to the previous year, underscoring the segment’s dominant role in shaping the broader treatment ecosystem.

Diagnostic testing conducted during active AHS outbreaks is the rapidly expanding segment, registering a CAGR of 10.5% in the coming years, driven by the rising frequency and geographic spread of outbreaks beyond traditional endemic zones. As AHS continues to emerge in new regions, rapid and accurate field diagnostics have become critical for containment and response planning.

Like, the number of AHS outbreaks outside Africa increased notably between 2020 and 2025, necessitating urgent deployment of real-time PCR kits, antigen detection assays, and mobile diagnostic units. In early 2025, Spain reported its first case since 2020, triggering immediate nationwide testing campaigns that relied heavily on advanced molecular diagnostics.

In addition, point-of-care diagnostic tools have gained traction in rural African settings, where traditional laboratory access is limited. Mobile diagnostic kits provided by organizations like the FAO have enabled faster identification of infected animals, reducing transmission risks and improving control measures. With climate change and global trade patterns continuing to influence disease dynamics, outbreak-driven diagnostics will remain a key growth engine in the AHS treatment market.

REGIONAL ANALYSIS

Africa remained at the dominant position in the African horse sickness treatment market, accounting for 62.2% of total market share in 2025. Being the endemic origin of the disease, the continent experiences recurring outbreaks, particularly in sub-Saharan regions where climatic conditions favor the proliferation of Culicoides midges the primary vectors of the virus. Despite efforts, challenges such as inadequate surveillance infrastructure and inconsistent vaccine coverage persist, contributing to ongoing disease transmission.

Government agencies and non-profit organizations have intensified collaboration with global health bodies to improve outbreak response capabilities. As per the World Organisation for Animal Health (WOAH), more than 15 African countries received technical assistance in 2025 to enhance laboratory diagnostics and field reporting systems. These developments underscore Africa’s central role not only in disease prevalence but also in shaping the trajectory of the global AHS treatment landscape.

Europe is seeing a rise in threats in the African horse sickness treatment market, driven primarily by the re-emergence of the disease in Mediterranean regions. Historically free of sustained AHS circulation, several European countries, including Spain, Portugal, and Italy, have experienced sporadic outbreaks in recent years, attributed to climate-induced expansion of competent insect vectors.

Also, the European Commission has responded by strengthening import regulations and investing in cross-border disease monitoring networks. As per the European Food Safety Authority (EFSA), over €15 million was allocated in 2023 for AHS preparedness, including stockpiling vaccines and enhancing diagnostic capacity in high-risk areas.

With equine industries playing a significant economic role in many EU countries, the threat of AHS has spurred proactive investment in prevention and treatment strategies, positioning Europe as a growing contributor to the global AHS treatment market.

The Middle East is another significant player in the African horse sickness treatment market, driven by its status as a major hub for international equine trade and equestrian events. Countries such as Saudi Arabia, the United Arab Emirates, and Qatar maintain large equine populations, including racehorses, show horses, and breeding stock, making them vulnerable to AHS incursions.

According to the World Organisation for Animal Health (WOAH), the UAE and Saudi Arabia reported multiple AHS cases in 2023, prompting swift implementation of emergency vaccination campaigns and strict quarantine protocols. These measures reflect the region’s growing emphasis on biosecurity and disease prevention, particularly in anticipation of major international equestrian competitions hosted annually.

As per the Food and Agriculture Organization (FAO), Gulf Cooperation Council (GCC) member states have invested heavily in equine health infrastructure, including modern diagnostic laboratories and cold-chain vaccine distribution networks. These strategic interventions reinforce the Middle East’s significance in the global AHS treatment market, particularly as a bridge between African and Eurasian disease dynamics.

The Asia-Pacific is an emerging risk zone in the African horse sickness treatment market, with India and Thailand being the primary contributors due to documented AHS cases in recent years. Although historically considered low-risk, the region faces growing concerns regarding disease introduction via imported equines, particularly for racing and breeding purposes. Despite efforts, awareness and preparedness levels remain low across much of the region. Fisheries and Forestry, only three countries in the Asia-Pacific region have established AHS contingency plans, leaving others vulnerable to future outbreaks.

Diagnostic capabilities for AHS in the region are still developing, with reliance on external reference labs delaying response times. However, increasing investment in equine healthcare and stricter import controls suggest a gradual uptick in regional engagement with AHS treatment and prevention strategies.

North America is maintaining a strong focus on preventive measures despite no endemic transmission. The United States and Canada have robust equine import regulations, requiring proof of AHS vaccination and negative test results for horses entering from affected regions.

According to the U.S. Department of Agriculture (USDA), over 10,000 equines were screened for AHS upon entry into the U.S. in 2023, with stringent quarantine procedures enforced for those arriving from high-risk countries. The USDA-APHIS also maintains a national AHS vaccine bank to ensure rapid response capability should an incursion occur.

Canadian and American veterinary institutions collaborate closely with WOAH and FAO on research initiatives aimed at improving diagnostics and vaccine efficacy. As per the University of Kentucky’s Gluck Equine Research Center, North American scientists contributed to the development of next-generation AHS vaccines currently undergoing trials in Europe and Africa. Although disease incidence remains minimal, the region’s well-funded veterinary infrastructure and regulatory vigilance place it as a key player in global AHS preparedness, ensuring readiness in the event of future threats.

COMPETITIVE LANDSCAPE

KEY MARKET PLAYERS

Veterinary Serum and Vaccine Research Institute and Onderstepoort Biological Products SOC Ltd are a few promising companies operating in the global African horse sickness treatment market.

The African horse sickness treatment market features a competitive yet specialized landscape dominated by a few global veterinary pharmaceutical and diagnostics firms. These companies operate in a niche domain where technical expertise, regulatory compliance, and logistical capabilities play a decisive role in market positioning. While established players such as Boehringer Ingelheim and Ceva Santé Animale lead in vaccine development and distribution, emerging biotech firms and regional manufacturers are increasingly entering the space, particularly in diagnostics and localized treatment solutions.

Competition is not only driven by product innovation but also by the ability to deliver scalable, cost-effective interventions in resource-limited settings. The demand for improved surveillance and rapid-response mechanisms has prompted firms to invest heavily in field diagnostics and mobile testing units. Additionally, the growing threat of AHS expansion beyond Africa due to climate change and international equine movement has intensified strategic alliances between private sector firms and global animal health bodies.

Despite limited commercial volume compared to other veterinary markets, the urgency associated with AHS outbreaks ensures sustained interest from key players aiming to strengthen their portfolio in high-impact animal diseases. As awareness grows and regulatory frameworks evolve, competition is expected to intensify further, particularly in vaccine accessibility and cross-border disease management.

Top Players in the Market

Boehringer Ingelheim Animal Health
Boehringer Ingelheim is a leading global player in veterinary pharmaceuticals and a key contributor to the African horse sickness treatment market. The company plays a pivotal role in vaccine development and distribution, offering critical immunization solutions that support both endemic and at-risk regions. With extensive research capabilities and a strong presence in equine health, Boehringer Ingelheim collaborates with international animal health organizations to enhance disease prevention strategies and ensure vaccine accessibility in high-risk zones.

Ceva Santé Animale
Ceva Santé Animale is another major participant in the AHS treatment landscape, known for its commitment to developing innovative vaccines and diagnostic tools tailored for vector-borne equine diseases. The company has been instrumental in advancing live-attenuated and recombinant vaccine technologies, contributing significantly to regional immunization programs. Ceva’s focus on sustainable animal health solutions has positioned it as a trusted partner in managing transboundary animal diseases like AHS.

IDEXX Laboratories

IDEXX Laboratories leads in veterinary diagnostics and plays a crucial role in AHS detection and monitoring. The company provides advanced diagnostic kits and laboratory services that support early identification of outbreaks and help guide containment efforts. IDEXX’s integration of digital reporting systems enhances surveillance capabilities, enabling faster response times across national and international borders, making it an essential player in the global fight against AHS.

Top Strategies Used by Key Market Participants

One of the primary strategies adopted by key players in the African horse sickness treatment market is intensified R&D investment , focusing on next-generation vaccines and more accurate diagnostic tools to address evolving viral strains and improve efficacy. This includes exploring mRNA-based vaccine platforms and multi-serotype protection models.

Another strategic approach is strategic partnerships and collaborations , where companies work closely with government agencies, international organizations, and academic institutions to accelerate research, gain regulatory approvals, and distribute treatments more efficiently across affected regions.

Lastly, expansion into emerging markets is a growing trend among industry leaders, who are strengthening their supply chains and establishing local partnerships to ensure timely delivery of vaccines and diagnostics in high-risk areas, particularly in sub-Saharan Africa and South Asia, thereby reinforcing their market presence and impact.

GLOBAL AFRICAN HORSE SICKNESS TREATMENT MARKET NEWS

• In February 2023, Boehringer Ingelheim launched a new mobile diagnostic initiative aimed at supporting field veterinarians in remote African regions, enhancing real-time detection and reporting of AHS cases to improve outbreak response efficiency.
• In July 2023, Ceva Santé Animale announced a collaborative agreement with the African Union to scale up vaccine production and distribution across member states, ensuring broader access to AHS immunization programs in endemic zones.
• In November 2023, IDEXX Laboratories introduced a next-generation AHS-specific PCR test kit designed for rapid field deployment, significantly improving early diagnosis and containment capabilities in both developed and developing countries.
• In March 2025, MSD Animal Health partnered with the World Organisation for Animal Health (WOAH) to co-develop training modules for veterinary professionals focused on AHS surveillance, diagnostics, and emergency preparedness in high-risk regions.
• In August 2025, Zoetis initiated a pilot program exploring RNA-based vaccine technology for AHS, marking a significant shift toward advanced immunization approaches that could offer broader serotype coverage and improved safety profiles.

MARKET SEGMENTATION

This market research report on the global African horse sickness treatment market has been segmented and sub-segmented into the following categories.

By Clinical Form

• Mixed Form of AHS
• Pulmonary (Dunkop) Form of AHS

By Diagnosis

• Preventive Diagnosis
• Diagnostic Testing During Outbreaks

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• The Middle East and Africa